Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

Exclusion Criteria

• •Fibromuscular dysplasia of renal artery or other non-atherosclerotic renal artery stenosis
• •Other secondary form of hypertension excluded on the basis of a clinical, hormonological and/or imaging work-up
• •Restenosis after a previous renal angioplasty or stenting
• •Only a stenosis of an accessory renal artery supplying \<1/2 of the ipsilateral renal parenchyma
• •Additional indication of ARAS stenting (Malignant hypertension, ≥ 30% increase in plasma creatinine after renin angiotensin system (RAS) blocker or after RAS blocker and diuretic administration, flash pulmonary edema)
• •Kidney pole-to-pole length \< 70 mm
• •Vascular disease precluding access for stenting
• •Abrupt vessel closure or dissection after diagnostic angiography
• •Contraindication to renal artery stenting according the notice for use of the stents
• •eGFR \< 20 ml/min/1.73 m² (MDRD)
• •History of transient ischemic accident (TIA) or cerebrovascular accident (CVA) during the 3 months prior to visit 1
• •History of acute heart failure or heart failure (NYHA class III-IV) within the 3 months prior to visit 1
• •History of myocardial infarction, unstable angina, coronary bypass or percutaneous coronary angioplasty during the 3 months prior to visit 1
• •Abdominal aortic aneurysm with indication for surgery or EVAR (Endovascular Aneurysm Repair)
• •Known history of cholesterol embolism
• •Brachial circumference of ≥ 42 cm
• •Severe contrast media allergy, not amenable to pre-treatment
• •Allergy to aspirin or clopidogrel
• •Atrial fibrillation
• •Comorbid condition causing life expectancy ≤ 3 years
• •Unlikely to co-operate in the study and/or poor compliance anticipated by the investigator
• •Participant not affiliated to the French social security
• •Pregnancy or breastfeeding
• •Guardianship for incapacity